Eyenovia, INC 10-Q quarterly reports

Hyperion DeFi, Inc. reported a significant shift to profitability in Q1 2026, driven by substantial gains in its digital asset strategy, while its ophthalmic technology segment winds down.

Hyperion DeFi, Inc. announced a significant financial turnaround in Q3 2025, reporting net income and a substantial increase in assets driven by its strategic pivot to the Hyperliquid ecosystem.

Hyperion DeFi reports a strategic pivot to a HYPE digital token treasury, significant capital raise, and debt restructuring, alongside ongoing ophthalmic device development, despite continued net losses.

Eyenovia, Inc. reports reduced net losses in Q1 2025 while advancing its Optejet platform and exploring strategic alternatives.

Eyenovia's Q3 2024 results show continued commercialization efforts and strategic collaborations, alongside a net loss and ongoing concerns about the company's ability to continue as a going concern.

Eyenovia's Q2 2024 results show a net loss, increased R&D spending, and the reacquisition of rights to its MicroPine product.

Eyenovia reacquired rights to its MicroPine product and reported a net loss of $10.9 million for the first quarter of 2024.